Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...
It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...
In a report released today, Laura Chico from Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback